Sen. Adam Schiff (D-Calif.) is sounding the alarm on the Trump administration's approach to federal research funding, warning that the cuts could cost America its status as the world's innovation leader and hand rivals an opening in critical fields like artificial intelligence.

Schiff Warns US Tech Leadership Is at Risk

On Wednesday, Schiff took aim at the administration's research funding strategy, arguing that reduced support could undermine the nation's competitive edge. "The United States is the world's leader in science and innovation, a role we've played for more than a century," he said. He added, "The Trump administration's endless attacks on research funding put that position of preeminence at risk."

Schiff emphasized that sustained investment in scientific research has been the backbone of U.S. dominance in advanced technology, AI, medicine, and other emerging industries. "We cannot let these harmful policies be the reason we forfeit our lead in cutting-edge technology to our competitors," he wrote.

Economic Impact of Science Cuts

In a letter to President Trump, Schiff urged a reversal of what he called "destructive cuts" to science and research funding, warning that reduced federal investment could jeopardize life-saving medical research, space exploration, and technological innovation. "Without robust federal funding and prioritization of our scientific workforce, we are at grave risk of ceding influence and power to our competitors abroad," he wrote.

The California senator also highlighted the broader economic stakes, citing researchers' estimates of $2.8 billion in losses from disrupted National Institutes of Health and National Science Foundation grants. He noted that a 25% cut in federal research and development spending could reduce U.S. GDP by a rate comparable to the Great Recession.

Trump Pushes AI Chips Funding, Psychedelic Research

Interestingly, the administration isn't cutting all science spending. Last month, the Commerce Department announced $874 million in CHIPS Act incentives for seven semiconductor companies developing AI and high-performance computing technologies, with the government taking minority stakes in those firms. And in April, Trump directed the FDA to speed up reviews of psychedelic treatments, including ibogaine, committing $50 million to study its potential for treating PTSD.

So while the administration is investing in some areas, Schiff argues the broader cuts to research funding are a dangerous gamble. The question is whether the U.S. can maintain its edge without the robust federal support that has fueled decades of innovation.

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by MarketDash editors.